Transposon Therapeutics, Inc.
Clinical trials sponsored by Transposon Therapeutics, Inc., explained in plain language.
-
New drug shows promise for genetic forms of ALS and dementia
Disease control CompletedThis study tested an experimental drug called TPN-101 in 42 people with ALS or frontotemporal dementia caused by a specific gene change (C9orf72). The main goal was to see if the drug is safe and tolerable over 48 weeks. Researchers also looked at how the drug moves in the body a…
Phase: PHASE2 • Sponsor: Transposon Therapeutics, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New drug tested for rare brain disease PSP
Disease control CompletedThis study tested a drug called TPN-101 in 42 people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and thinking. The main goal was to see if the drug is safe and tolerable over 48 weeks. Researchers also looked at how the drug moves in the …
Phase: PHASE2 • Sponsor: Transposon Therapeutics, Inc. • Aim: Disease control
Last updated Jun 09, 2026 12:08 UTC